ClinicalTrials.gg
CompletedNCT01618162DUAL™IVUpdated Oct 27, 2017Results posted

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

A Phase 3 interventional study of insulin degludec/liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 87 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-27.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
28th of 70
435 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
28th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 28th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled with SU (sulphonylurea) alone or in combination with metformin. All subjects will continue their pre-trial SU treatment with or without metformin treatment without changing the frequency or dose throughout the trial.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 435 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 2 diabetes mellitus
  • 7.0-9.0% (53-75 mmol/mol) (both inclusive)
  • Subjects on stable daily dose of sulphonylurea (above or equal to half of the max approved dose according to local label) with or without metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening visit (Visit 1)
  • (BMI) below or equal to 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any use of oral anti-diabetic drugs (OADs) (other than SU in monotherapy or in combinationwith metformin) below or equal to 90 days prior to screening visit (Visit 1)
  • Use of any drug (other than SU in monotherapy or in combination with metformin), which in the Investigators opinion could interfere with the blood glucose level (e.g. systemic )
  • Previous treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (e.g. exenatide, liraglutide)
  • Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator)
  • Screening calcitonin above or equal to 50 ng/l
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • Cardiovascular disorders defined as: congestive heart failure ( (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary,carotid or peripheral artery revascularisation procedures
  • Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion
  • Subjects with a clinical significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the Type 2 Diabetes Mellitus),neurological, genitourinary or haematological system that in the opinion of the Investigator,may confound the results of the trial or pose additional risk in administering trial product
  • History of chronic pancreatitis or idiopathic acute pancreatitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide

    Drug: insulin degludec/liraglutide

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

  • Drugplacebo

    Injected subcutaneously (under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change in HbA1c from baseline to 26 weeks.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)

    Percentage of subjects having HbA1c below 7% at week 26.

    Time frame: Week 26

  2. Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)

    Percentage of subjects having HbA1c below 6.5% at week 26

    Time frame: Week 26

  3. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG at week 26.

    Time frame: Week 0, week 26

  4. Change From Baseline in Body Weight

    Change from baseline in body weight at week 26.

    Time frame: Week 0, week 26

  5. Number of Treatment Emergent (Confirmed) Hypoglycaemic Episodes

    An event was treatment emergent if the onset of the episode occurs after the first administration of trial product and no later than 7 days after last trial product administration. Confirmed hypoglycaemic episodes were defined as hypoglycaemic episodes that were either severe or minor. Minor hypoglycaemic episodes were defined as: 1. An episode with symptoms consistent with hypoglycaemia and confirmed by blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) and which was handled by the subject himself/herself. 2. Any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or blood glucose value \<2.8 mmol/L (50 mg/dL). Severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Reported values are hypoglycemia event rate per 100 patient-years of exposure (PYE).

    Time frame: After 26 weeks of treatment

  6. Number of Adverse Events (AEs)

    An AE was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. Reported values are hypoglycemia event rate per 100 PYE.

    Time frame: After 26 weeks of treatment

08

Results

Posted Feb 17, 2017

Participant flow

The trial was conducted at 77 sites in 7 countries: Bulgaria (7), Canada (9), Germany (6), India (6), Israel (7), Turkey (3), United States (39).

Participant flow — Overall Study
MilestoneIDegLiraPlacebo
Started289146
Exposed288146
Completed251111
Not completed3835
Withdrew: Protocol violation1310
Withdrew: Adverse event92
Withdrew: Withdrawal criteria210
Withdrew: Unclassified1413

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change in HbA1c from baseline to 26 weeks.

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDegLiraPlacebo
Change in Glycosylated Haemoglobin (HbA1c)-1.45 ± 0.84-0.46 ± 0.83
Statistical analysis
  • IDegLira vs Placebo · ANCOVA · p = < 0.001 · Estimated treatment difference: -1.02 · 95% CI -1.18 to -0.87
SecondaryResponders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)

Percentage of subjects having HbA1c below 7% at week 26.

Time frame:
Week 26
Reported as:
Number · percentage of subjects
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)
percentage of subjectsIDegLiraPlacebo
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)79.228.8
SecondaryResponders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)

Percentage of subjects having HbA1c below 6.5% at week 26

Time frame:
Week 26
Reported as:
Number · percentage of subjects
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)
percentage of subjectsIDegLiraPlacebo
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)6412.3
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in FPG at week 26.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegLiraPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG)-2.6 ± 2.61-0.31 ± 2.43
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight at week 26.

Time frame:
Week 0, week 26
Reported as:
Mean · kilogram
Change From Baseline in Body Weight
kilogramIDegLiraPlacebo
Change From Baseline in Body Weight0.5 ± 3.1-1 ± 2.6
SecondaryNumber of Treatment Emergent (Confirmed) Hypoglycaemic Episodes

An event was treatment emergent if the onset of the episode occurs after the first administration of trial product and no later than 7 days after last trial product administration. Confirmed hypoglycaemic episodes were defined as hypoglycaemic episodes that were either severe or minor. Minor hypoglycaemic episodes were defined as: 1. An episode with symptoms consistent with hypoglycaemia and confirmed by blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) and which was handled by the subject himself/herself. 2. Any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or blood glucose value \<2.8 mmol/L (50 mg/dL). Severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Reported values are hypoglycemia event rate per 100 patient-years of exposure (PYE).

Time frame:
After 26 weeks of treatment
Reported as:
Number · event rate per 100 PYE
Number of Treatment Emergent (Confirmed) Hypoglycaemic Episodes
event rate per 100 PYEIDegLiraPlacebo
Number of Treatment Emergent (Confirmed) Hypoglycaemic Episodes351.7135.2
SecondaryNumber of Adverse Events (AEs)

An AE was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. Reported values are hypoglycemia event rate per 100 PYE.

Time frame:
After 26 weeks of treatment
Reported as:
Number · event rate per 100 PYE
Number of Adverse Events (AEs)
event rate per 100 PYEIDegLiraPlacebo
Number of Adverse Events (AEs)401.4367

Adverse events

Collected over After 26 weeks of treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira—14/288 (4.9%)83/288 (28.8%)
Placebo—5/146 (3.4%)38/146 (26%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventIDegLiraPlacebo
FallInjury, poisoning and procedural complications2/2880/146
Atrioventricular block second degreeCardiac disorders0/2881/146
BronchitisInfections and infestations0/2881/146
Dengue feverInfections and infestations0/2881/146
Impaired gastric emptyingGastrointestinal disorders0/2881/146
Stab woundInjury, poisoning and procedural complications0/2881/146
Acute myocardial infarctionCardiac disorders1/2880/146
Amylase increasedInvestigations1/2880/146
Anal abscessInfections and infestations1/2880/146
ArrhythmiaCardiac disorders1/2880/146
Most frequent other events
Most frequent other events
EventIDegLiraPlacebo
Lipase increasedInvestigations27/2886/146
NasopharyngitisInfections and infestations25/28812/146
DyslipidaemiaMetabolism and nutrition disorders19/2886/146
HeadacheNervous system disorders15/2888/146
InfluenzaInfections and infestations8/2888/146

Baseline characteristics

Full analysis set (FAS) included all randomized subjects.

Age, Continuous
Age, Continuous(years)IDegLiraPlaceboTotal
Mean60 ± 9.659.4 ± 10.859.8 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)IDegLiraPlaceboTotal
Female13573208
Male15473227
Glycosylated haemoglobin
Glycosylated haemoglobin(percentage of glycosylated haemoglobin)IDegLiraPlaceboTotal
Mean7.9 ± 0.67.9 ± 0.67.9 ± 0.6
Fasting plasma glucose
Fasting plasma glucose(mmol/L)IDegLiraPlaceboTotal
Mean9.1 ± 2.29.1 ± 2.19.1 ± 2.1
Body weight
Body weight(kilograms)IDegLiraPlaceboTotal
Mean87.2 ± 18.689.3 ± 17.587.9 ± 18.2
09

Study locations

87 sites
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Garden Grove, California 92844, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90807, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32934, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Meridian, Idaho 83646, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Saint Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Lodi, New Jersey 076444, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Tabor City, North Carolina 28463, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45220-2213, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Mason, Ohio 45040-6815, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104-5020, United States
  • Novo Nordisk Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19152, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Pelzer, South Carolina 29669, United States
  • Novo Nordisk Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Novo Nordisk Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75203, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75251, United States
  • Novo Nordisk Investigational Site
    Hurst, Texas 76054, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23219, United States
  • Novo Nordisk Investigational Site
    Lukovit, 5770, Bulgaria
  • Novo Nordisk Investigational Site
    Ruse, 7000, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1324, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1431, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1606, Bulgaria
  • Novo Nordisk Investigational Site
    Burnaby, British Columbia V5G 1T4, Canada
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • Novo Nordisk Investigational Site
    Victoria, British Columbia V8V 3N7, Canada
  • Novo Nordisk Investigational Site
    Cambridge, Ontario N1R 7L6, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6G 2M1, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • Novo Nordisk Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • Novo Nordisk Investigational Site
    Pointe Claire, Quebec H9R 4S3, Canada
  • Novo Nordisk Investigational Site
    Sherbrooke, Quebec J1G 5K2, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1N 4V3, Canada
  • Novo Nordisk Investigational Site
    Esslingen, 73728, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Pohlheim, 35415, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Sulzbach-Rosenberg, 92237, Germany
  • Novo Nordisk Investigational Site
    Guwahati, Assam 781007, India
  • Novo Nordisk Investigational Site
    Guwahati, Assam, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560043, India
  • Novo Nordisk Investigational Site
    Belgaum, Karnataka 590001, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400008, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411030, India
  • Novo Nordisk Investigational Site
    Delhi, New Delhi 110002, India
  • Novo Nordisk Investigational Site
    Hyderabad, 600034, India
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Petah-Tikva, 49100, Israel
  • Novo Nordisk Investigational Site
    Tel Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 64239, Israel
  • Novo Nordisk Investigational Site
    Manati, 00674, Puerto Rico
  • Novo Nordisk Investigational Site
    Ankara, 06110, Turkey
  • Novo Nordisk Investigational Site
    Antalya, 07058, Turkey
  • Novo Nordisk Investigational Site
    Gaziantep, 27070, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34752, Turkey
  • Novo Nordisk Investigational Site
    Izmir, 35100, Turkey
10

References and documents

Publications

  • Khunti K, Mohan V, Jain SM, Boesgaard TW, Begtrup K, Sethi B. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Ther. 2017 Jun;8(3):673-682. doi: 10.1007/s13300-017-0252-9. Epub 2017 Mar 22. PubMed 28332144 ↗
  • Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7. PubMed 27589252 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Oct 2013, 13 months.

Results were first posted in Feb 2017, 3 years 3 months after primary completion. A results delay was requested in Nov 2013.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2012
First posted
Jun 13, 2012
StartActual
Aug 29, 2012
Primary completionActual
Oct 23, 2013
CompletionActual
Oct 23, 2013
Results delay requested
Nov 7, 2013
Results first posted
Feb 17, 2017
Last update
Oct 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01618162
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 13, 2012
Start date
Aug 29, 2012
Primary completion
Oct 23, 2013
Completion
Oct 23, 2013
Results posted
Feb 17, 2017
Last update
Oct 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion